



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




Pralsetinib

Item No. 33181

CAS Registry No.: 2097132-94-8
Formal Name: *cis*-N-[(1*S*)-1-[6-(4-fluoro-1*H*-pyrazol-1-yl)-3-pyridinyl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1*H*-pyrazol-3-yl)amino]-2-pyrimidinyl]-cyclohexanecarboxamide

Synonym: BLU-667
MF: C₂₇H₃₂FN₉O₂
FW: 533.6
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pralsetinib is supplied as a solid. A stock solution may be made by dissolving the pralsetinib in the solvent of choice, which should be purged with an inert gas. Pralsetinib is soluble in DMSO. Pralsetinib is slightly soluble in water and methanol.

Description

Pralsetinib is an inhibitor of RET (IC₅₀s = 0.4, 0.3, 0.4, and 0.4 nM for wild-type RET, RET^{V804L}, RET^{V804M}, and RET^{M918T}, respectively).¹ It is selective for RET over VEGFR2 (IC₅₀ = 35 nM) and a panel of 371 kinases at 300 nM. Pralsetinib also inhibits a fusion protein of coiled-coil domain-containing protein 6 with RET (CCDC6-RET) and autophosphorylation of RET in Ba/F3 cells expressing a fusion protein of kinesin-1 heavy chain with RET (KIF5B-RET; IC₅₀s = 0.4 and 5 nM, respectively). It induces tumor regression in a KIF5B-RET-positive patient-derived xenograft (PDX) mouse model of non-small cell lung cancer (NSCLC) when administered at a dose of 30 mg/kg. Formulations containing pralsetinib have been used in the treatment of metastatic RET-fusion-positive NSCLC.

Reference

1. Subbiah, V., Gainor, J.F., Rahal, R., *et al.* Precision targeted therapy with BLU-667 for RET-driven cancers. *Cancer Discov.* **8**(7), 836-849 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/16/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM